Catalent Crecimiento futuro

Future controles de criterios 3/6

Catalent se prevé un crecimiento anual de los beneficios y los ingresos de 83.4% y 5.6% respectivamente. Se prevé que el BPA sea de grow en 84.6% al año. Se prevé que la rentabilidad de los fondos propios sea de 7.4% en 3 años.

Información clave

92.3%

Tasa de crecimiento de los beneficios

92.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	20.8%
Tasa de crecimiento de los ingresos	7.2%
Rentabilidad financiera futura	7.7%
Cobertura de analistas	Good
Última actualización	09 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal

Jan 05

An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Dec 27

Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute

Dec 22

Catalent falls after new short call from Glasshouse Research

Dec 08

Catalent Q1 2023 Earnings Preview

Oct 31

These 4 Measures Indicate That Catalent (NYSE:CTLT) Is Using Debt Extensively

Oct 26

Catalent: Charting A Post-Covid Future

Oct 19

Calculating The Fair Value Of Catalent, Inc. (NYSE:CTLT)

Sep 16

Catalent Non-GAAP EPS of $1.19 beats by $0.04, revenue of $1.31B misses by $20M

Aug 29

Previsiones de crecimiento de beneficios e ingresos

NYSE:CTLT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2026	4,986	219	187	651	9
6/30/2025	4,645	76	154	563	12
6/30/2024	4,376	-804	-163	475	12
12/31/2023	4,098	-1,302	-263	174	N/A
9/30/2023	4,223	-1,015	-235	276	N/A
6/30/2023	4,263	-256	-322	254	N/A
3/31/2023	4,495	21	-563	127	N/A
12/31/2022	4,731	389	-371	329	N/A
9/30/2022	4,799	399	-471	184	N/A
6/30/2022	4,802	483	-221	439	N/A
3/31/2022	4,703	485	-110	504	N/A
12/31/2021	4,483	561	-183	441	N/A
9/30/2021	4,177	544	-244	446	N/A
6/30/2021	3,998	529	-253	433	N/A
3/31/2021	3,757	494	-188	471	N/A
12/31/2020	3,465	289	-135	518	N/A
9/30/2020	3,275	250	22	565	N/A
6/30/2020	3,094	173	-26	440	N/A
3/31/2020	2,872	104	-37	356	N/A
12/31/2019	2,729	124	20	309	N/A
9/30/2019	2,631	138	-22	232	N/A
6/30/2019	2,518	132	30	248	N/A
3/31/2019	2,478	149	75	263	N/A
12/31/2018	2,488	136	108	283	N/A
9/30/2018	2,471	65	160	332	N/A
6/30/2018	2,463	84	198	375	N/A
3/31/2018	2,395	63	202	371	N/A
12/31/2017	2,300	70	211	380	N/A
9/30/2017	2,177	109	N/A	335	N/A
6/30/2017	2,075	110	N/A	300	N/A
3/31/2017	1,991	106	N/A	233	N/A
12/31/2016	1,896	91	N/A	180	N/A
9/30/2016	1,867	104	N/A	159	N/A
6/30/2016	1,848	112	N/A	155	N/A
3/31/2016	1,826	207	N/A	199	N/A
12/31/2015	1,835	228	N/A	243	N/A
9/30/2015	1,836	244	N/A	257	N/A
6/30/2015	1,831	212	N/A	172	N/A
3/31/2015	1,840	86	N/A	180	N/A
12/31/2014	1,847	62	N/A	138	N/A
9/30/2014	1,832	-3	N/A	113	N/A
6/30/2014	1,828	19	N/A	178	N/A
3/31/2014	1,813	2	N/A	148	N/A
12/31/2013	1,807	-20	N/A	152	N/A
9/30/2013	1,803	-29	N/A	151	N/A
6/30/2013	1,800	-51	N/A	138	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. tasa de ahorro: CTLT se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios frente mercado: CTLT se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: CTLT se espera que sea rentable en los próximos 3 años.

Ingresos vs. Mercado: CTLT(5.6% al año) se prevé que crezca más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: CTLTSe prevé que los ingresos de la empresa (5.6% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Futura rentabilidad financiera (ROE): CTLTSe prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (7.4%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Catalent Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Price target decreased by 7.6% to US$63.17

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 10%

Price target increased by 11% to US$82.36

Recent updates

Catalent, Inc. announced delayed 10-Q filing

Insufficient new directors

Catalent - Novo Holdings Merger: Attractive Spread

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent: Debt Remains An Overhang

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent Remains Overvalued

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings: EPS misses analyst expectations

Catalent, Inc. Announces Board Changes

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Calculating The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Insufficient new directors

Catalent, Inc. Announces Executive Changes

Catalent: Myriad Issues To Fix

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

New minor risk - Earnings quality

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Price target decreased by 7.6% to US$63.17

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Now 30% undervalued after recent price drop

Catalent (NYSE:CTLT) Has A Somewhat Strained Balance Sheet

Insider recently sold US$72k worth of stock

Investor sentiment improves as stock rises 15%

Now 22% undervalued after recent price drop

Consensus EPS estimates fall by 10%

Investor sentiment deteriorates as stock falls 29%

A Look At The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Price target increased by 11% to US$82.36

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Danaher Reportedly Expresses Takeover Interest in Catalent

Investor sentiment improves as stock rises 27%

Why did Catalent stock soar today? Potential takeover by Danaher

We Think Catalent (NYSE:CTLT) Is Taking Some Risk With Its Debt

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal

An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute

Catalent, Inc. Announces Director Changes

Catalent falls after new short call from Glasshouse Research

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Price target decreased to US$76.00

Investor sentiment deteriorated over the past week

Insider recently sold US$161k worth of stock

Price target decreased to US$91.50

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Catalent Q1 2023 Earnings Preview

These 4 Measures Indicate That Catalent (NYSE:CTLT) Is Using Debt Extensively

Catalent: Charting A Post-Covid Future

Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022

Now 21% undervalued after recent price drop

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.